Desarrollo de Fármacos

Área de la Ciencia:

• Computational biology and bioinformatics
• Neuroscience and neurodegenerative diseases
• Pharmacology and drug discovery

Sus antecedentes:

• Traumatic Brain Injury (TBI) is a significant risk factor for Alzheimer's disease (AD), yet effective treatments remain limited.
• Network-medicine techniques integrating gene set data and electronic health records (EHRs) show promise for identifying drug repurposing candidates.
• This study focuses on preventing AD in elderly populations and individuals with a history of TBI.

Objetivo del estudio:

• To identify potential drug repurposing candidates for Alzheimer's disease (AD) prevention using a network-based approach.
• To validate network-predicted drugs through analysis of large-scale real-world patient data.
• To investigate the efficacy of identified drugs in reducing AD incidence in at-risk populations.

Principales métodos:

• A network-based algorithm assessed gene set connectedness in a protein-protein interactome (PPI) network using permutation tests.
• The algorithm linked human interactome and drug-target networks to rank potential drug candidates.
• Top candidates were evaluated using MarketScan® insurance claims data, focusing on patients over 70.

Principales resultados:

• Network analysis generated ranked drug lists based on 69 TBI and 144 AD genes.
• Doxycycline prescription was associated with a significantly lower risk of AD development (RR=0.92, p=0.002) compared to anti-infectives and antibiotics.
• Potential mechanisms include modulation of microglial activity and blood-brain barrier integrity.

Conclusiones:

• Combining network-based predictions with real-world patient data effectively identifies repurposable drugs for AD prevention.
• Doxycycline emerges as a promising candidate treatment for preventing Alzheimer's disease.
• The study highlights the potential of network medicine in drug discovery for neurodegenerative diseases.